TI
MLTX icon

Trexquant Investment’s MoonLake Immunotherapeutics MLTX Stock Holding History

Trexquant Investment’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.36M Sell
377,946
-117,390
-24% -$2.13M 0.04% 567
2026
Q1 		$9.23M Buy
495,336
+311,017
+169% +$5.15M 0.07% 400
2025
Q4 		$2.43M Buy
+184,319
New +$2.17M 0.02% 919
2024
Q4 		– Sell
-25,523
Closed -$1.29M – 1740
2024
Q3 		$1.29M Buy
+25,523
New +$1.2M 0.02% 964
2024
Q2 		– Sell
-9,697
Closed -$487K – 1733
2024
Q1 		$487K Buy
+9,697
New +$526K 0.01% 1154

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Trexquant Investment's MLTX Position: Q2 2026 in Review

Trexquant Investment reduced its MoonLake Immunotherapeutics (MLTX) stake by 24% in Q2 2026, selling an estimated $2.13M and leaving 377,946 shares worth $7.36M. The position accounts for 0.04% of the portfolio, ranked #567.

Trexquant Investment first reported a position in MLTX in Q1 2024 and has held it in 5 quarters since. The position peaked at $9.23M in Q1 2026. 173 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

  • Trexquant Investment held 377,946 shares of MoonLake Immunotherapeutics worth $7.36M as of Q2 2026.
  • Trexquant Investment sold 117,390 MoonLake Immunotherapeutics shares in Q2 2026, an estimated $2.13M.
  • MoonLake Immunotherapeutics made up 0.04% of Trexquant Investment's portfolio in Q2 2026, its #567 holding.
  • Trexquant Investment first reported a position in MoonLake Immunotherapeutics in Q1 2024 and has held it in 5 quarters since.
  • Trexquant Investment's MoonLake Immunotherapeutics position peaked at $9.23M in Q1 2026.
  • 173 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on Trexquant Investment's 13F filing for Q2 2026, filed 14 Aug 2026.